ASCO
Pharma

Akeso's 34% overall survival win comes with caveats

While ivonescimab and chemo's 34% improvement on overall survival exceeded expectations, detailed data from Harmoni-6 are being picked apart.
Angus Liu May 31, 2026 8:00am
A series of dice with a bag on them illustrating cost cuts

Merck lays off 88 staffers tied to New Jersey headquarters

Jun 2, 2026 11:10am
Gilead

With trial success, Gilead paves way for broader use of Livdelzi

Jun 2, 2026 10:55am
Ebola Ebola virus Ebolavirus outbreak

Merck eyes COVID antiviral Lagevrio amid Ebola outbreak

Jun 2, 2026 10:40am
red light stop light street traffic signal

Cingulate hit with manufacturing-related FDA rejection

Jun 2, 2026 9:53am
spermatozoa sperm and egg conception contraception birth control family planning

Contraline gins up $92.5M in male birth control development push

Jun 2, 2026 8:00am
More News

Eisai whips up Alzheimer’s guidance to expand nutrition program

Jun 2, 2026 5:44am
Fierce Healthcare

Trump signs off on HHS overhaul of childhood vaccine schedule

Jun 1, 2026 2:00pm

Shionogi's Japan-approved antiviral nets US COVID nod

Jun 1, 2026 11:11am

The Oral GLP-1 Tracker: Jefferies reaffirms Foundayo forecast

Jun 1, 2026 9:23am